[go: up one dir, main page]

AU2712899A - Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates - Google Patents

Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates

Info

Publication number
AU2712899A
AU2712899A AU27128/99A AU2712899A AU2712899A AU 2712899 A AU2712899 A AU 2712899A AU 27128/99 A AU27128/99 A AU 27128/99A AU 2712899 A AU2712899 A AU 2712899A AU 2712899 A AU2712899 A AU 2712899A
Authority
AU
Australia
Prior art keywords
glp
helix
aggregates
percent
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27128/99A
Inventor
Soren Erik Bjorn
Per Olaf Huusfeldt
Niels C. Kaarsholm
Liselotte Bjerre Knudsen
Per Franklin Nielsen
Helle Birk Olsen
Lars Thim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2712899A publication Critical patent/AU2712899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU27128/99A 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates Abandoned AU2712899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK271/98 1998-02-27
DK27198 1998-02-27
PCT/DK1999/000080 WO1999043361A1 (en) 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates

Publications (1)

Publication Number Publication Date
AU2712899A true AU2712899A (en) 1999-09-15

Family

ID=8091669

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27128/99A Abandoned AU2712899A (en) 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates

Country Status (4)

Country Link
EP (1) EP1060192A2 (en)
JP (1) JP2002504527A (en)
AU (1) AU2712899A (en)
WO (1) WO1999043361A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
EP1326630B1 (en) 2000-09-18 2008-05-28 Sanos Bioscience A/S Use of glp-2 peptides
AU2002233089B2 (en) 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
CN1771080B (en) 2003-04-08 2010-12-15 诺沃挪第克公司 Method for producing a therapeutic polypeptide or a precursor thereof comprising at least one chromatographic step
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
EP2292254A3 (en) 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN1812808B (en) 2003-06-03 2012-07-04 诺沃挪第克公司 Stabilized pharmaceutical peptide compositions
CN101380476A (en) * 2003-09-19 2009-03-11 诺沃挪第克公司 Albumin-binding derivatives of therapeutic peptides
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US20070203058A1 (en) * 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
RU2401276C2 (en) * 2003-09-19 2010-10-10 Ново Нордиск А/С Glucagon-like peptide-1 (glp-1) derivatives
US7847061B2 (en) 2004-11-01 2010-12-07 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
WO2006097535A2 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
JP5755398B2 (en) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス Elongated GLP-1 compound
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN100418983C (en) * 2005-05-11 2008-09-17 中国药科大学 Human glucagon related peptide-2 analog
JP2011520844A (en) 2008-05-15 2011-07-21 ノボ・ノルデイスク・エー／エス Purification of peptides prepared by solid phase synthesis
CA2733200A1 (en) 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
RU2539797C2 (en) 2009-01-22 2015-01-27 Ново Нордиск Хелс Кеа Аг Human growth hormone derivative highly resistant to proteolytic degradation, method for preparing this derivative, using it, method of treating, and pharmaceutical composition
CN105963710A (en) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 Growth hormones with prolonged in-vivo efficacy
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
BR112012018116B1 (en) 2010-01-22 2022-06-21 Novo Nordisk Health Care Ag Growth hormone conjugates with prolonged in vivo efficacy
JP6464145B2 (en) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone compound preparation
WO2019086559A1 (en) 2017-10-31 2019-05-09 Adocia Composition comprising a glp-2 receptor agonist and a co-polyamino acid carrying carboxylate charges and hydrophobic radicals
CA3129576A1 (en) 2019-02-11 2020-08-20 Opko Biologics Ltd. Long-acting glp-2 analogs
WO2022157747A2 (en) 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100310122B1 (en) * 1993-09-17 2002-04-24 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 Acylated Insulin
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
IL125805A0 (en) * 1996-03-01 1999-04-11 Novo Nordisk As Use of a pharmaceutical composition comprising an appetite-suppressing peptide
AU733857B2 (en) * 1996-04-12 2001-05-31 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
WO1998008872A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives

Also Published As

Publication number Publication date
WO1999043361A8 (en) 1999-10-14
EP1060192A2 (en) 2000-12-20
JP2002504527A (en) 2002-02-12
WO1999043361A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
AU2712899A (en) Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
AU2001230026A1 (en) 2,4-diaminothiazole derivatives
AU2001294606A1 (en) Substituted azepino(4,5b)indoline derivatives
PT1589017E (en) 12,13-modified epothilone derivatives
AU1444800A (en) Microscale patterning and articles formed thereby
AU2001244618A1 (en) Substituted 1,3-thiazole compounds, their production and use
AU6162398A (en) Polymer nanocomposite composition
AU4112497A (en) Glp-2 derivatives
AU6636598A (en) Novel 3,4-dialkoxyphenyl derivatives and the use thereof
AU3819200A (en) 2,4-diamino-pyrimidine derivatives
AU2507801A (en) Naphthopyrans with a heterocycle in the 5,6-position, preparation, and compositions and matrices containing them
AU3501800A (en) Aqueous dispersion composition and manufacturing method for the composition
EP1469001B8 (en) Corroles, including chiral derivatives and the use thereof
AU2001294240A1 (en) 2,2-diphenylbutanamide derivatives and medicines containing the same
AU6102599A (en) Melt-mouldable composites
AU5176299A (en) Compound, composition and use
AU1979799A (en) Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers
AU2964899A (en) 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
AU3880399A (en) Octahydropyrrolo-(3,4-c)carbazoles useful as analgesic agents
AU1513597A (en) 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives
AU2846099A (en) 1,3,4-thiadiazolylazo dyes and ink compositions containing the same
AU9029898A (en) 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives
AU2001256791A1 (en) 5,6-trans-2-alkylvitamin d derivatives
AU2001232226A1 (en) 1,3,4-oxadiazole derivatives and process for producing the same
AU3055199A (en) Process for producing hydroxyiminoacetamide derivative and process for producingmethoxyiminoacetamide derivative with the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase